Drug Monograph

Drug/Drug Class:	**Cetylev® (acetylcysteine) effervescent tablet/APAP Toxicity**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Cetylev® is available as an effervescent tablet containing either 500 mg or 2.5 gram acetylcysteine respectively.
Manufacturer:	Arbor Pharmaceuticals, LLC., Atlanta, GA 30328
Indications:	Cetylev® is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion.
Costs:	$18.08 per 2.5 gm tab and $3.61 per 500 mg tab of Cetylev®. Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 16, 2016

© 2016 Xerox Heritage, LLC All Rights Reserved.